AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Risk Factors for Low Lymphocyte Count in Patients With Type 2 Diabetes
Completed
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2010-09-01
- Last Posted Date
- 2016-12-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 16492
- Registration Number
- NCT01192659
Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin XR Tablet (Manufactured in Mt Vernon, IN) Relative to 5 mg Saxagliptin Tablet and 500 mg Metformin XR Tablet (Manufactured in Evansville, IN)
Phase 1
Completed
- Conditions
- Diabetes Mellitus
- Interventions
- First Posted Date
- 2010-08-31
- Last Posted Date
- 2015-05-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT01192139
- Locations
- 🇺🇸
Ppd Development, Lp, Austin, Texas, United States
Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin/1000 mg Metformin XR (Manufactured in Mt Vernon, IN) Relative to 5 mg of Onglyza and 2 × 500 mg Glucophage XR
Phase 1
Completed
- Conditions
- Diabetes Mellitus
- Interventions
- First Posted Date
- 2010-08-31
- Last Posted Date
- 2015-05-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT01192152
- Locations
- 🇺🇸
PPD Development, LP, Austin, Texas, United States
Lipid-lowering Therapy for Secondary Prevention in Patients Undergoing Elective Percutaneous Coronary Intervention (PCI)
Terminated
- Conditions
- Coronary Artery Disease
- First Posted Date
- 2010-08-27
- Last Posted Date
- 2013-01-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 120
- Registration Number
- NCT01190072
- Locations
- 🇸🇮
Research Site, Maribor, Slovenia
Dose Rate Range Finding Study of Propofol for minimal-to Moderate Sedation on Upper & Lower Endoscopic Tests
Phase 2
Completed
- Conditions
- Gastrointestinal EndoscopyGastrointestinal Polypectomy
- Interventions
- Drug: PlaceboDrug: ICI35,868 (propofol)
- First Posted Date
- 2010-08-26
- Last Posted Date
- 2011-12-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 123
- Registration Number
- NCT01189604
- Locations
- 🇯🇵
Research Site, Moriya, Ibaragi, Japan
Efficacy Study in Allergic Rhinitis Patients After Intranasal Administration of AZD8848
Phase 2
Completed
- Conditions
- Allergic Rhinitis
- Interventions
- First Posted Date
- 2010-08-19
- Last Posted Date
- 2016-01-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 93
- Registration Number
- NCT01185080
- Locations
- 🇸🇪
Research Site, Helsingborg, Sweden
To Study the Changes in Protein in Lung Cells of Asian Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
Not Applicable
Completed
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Procedure: Testing for mutation status
- First Posted Date
- 2010-08-19
- Last Posted Date
- 2011-08-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1270
- Registration Number
- NCT01185314
- Locations
- 🇻🇳
Research Site, Ho Chi Minh City, Vietnam
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder
Phase 3
Completed
- Conditions
- Major Depressive DisorderDepression
- Interventions
- Drug: Placebo
- First Posted Date
- 2010-08-12
- Last Posted Date
- 2014-04-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 295
- Registration Number
- NCT01180400
- Locations
- 🇸🇪
Research Site, Stockholm, Sweden
Observational Study on Non-steroid Anti-inflammatory Drugs (NSAIDs) Treated Patients With Arthritic Disorder
Completed
- Conditions
- OsteoarthritisRheumatoid ArthritisAnkylosing Spondylitis
- First Posted Date
- 2010-08-06
- Last Posted Date
- 2012-06-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1149
- Registration Number
- NCT01176682
- Locations
- 🇬🇧
Research Site, Woolpit, Bury St Edmonds, United Kingdom
Hypoglycemia: Physician and Patient Perspectives
Completed
- Conditions
- Type 2 Diabetes MellitusHypoglycemia
- First Posted Date
- 2010-08-06
- Last Posted Date
- 2011-09-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 800
- Registration Number
- NCT01176656